

**Table 2 : Data regarding different case series and reports**

Study ref	Country	Number of patients	Genetics	Indication	Amyloidosis	Dosage and route of administration	Mean duration of Tocilizumab treatment (months)	Outcomes	
								Efficacy	Safety
Karadeniz et al. 2020	Turkey	2	M694V/M694V	crFMF + amyloidosis	Yes (kidney)	IV 12 mg/kg monthly	4	NR	/
			M694V/- Tel Hashomer +	crFMF + Rheumatoid arthritis	No	?	/	NR	/
Inui et al. 2023	Japan	1	E148Q/M694I Tel Hashomer +	crFMF	Yes (kidney)	IV 8 mg/kg monthly	108	CR Decrease on amyloid deposits on repeated renal biopsies	/
Honda et al. 2021	Japan	1	M694I/- Tel Hashomer -	Protracted febrile myalgia with colchicine intolerance (GI symptoms)	No	SC 162 mg/ week	7	CR	/
Aikawa et al. 2019	Japan	1	E84K/ E148Q Tel Hashomer +	crFMF + amyloidosis	Yes (GI)	SC 162 mg/ 2 weeks	7	CR Amyloid deposition in ileum and colon disappeared	/
Umeda et al. 2017	Japan	1	E148Q/- Tel Hashomer +	crFMF	No	IV 8 mg/kg monthly	9	CR	/
Hamanoue et al. 2016	Japan	1	M694I/ E148Q Tel Hashomer +	crFMF	Yes (kidney + GI)	IV 8 mg/kg monthly	24	CR Decrease in GI amyloid	/

								deposition	
Serelis et al. 2015	Turkey	1	Exon 10 MFEV mutation ( ?) Tel Hashomer +	crFMF + amyloidosis	Yes (kidney)	IV 8 mg/kg monthly	50	CR	/
Yilmaz et al. 2015	Turkey	11	M694V/M694V =7 M694V/M680I= 2 E148Q/ E148Q= 1 Unknown= 1	crFMF + amyloidosis	Yes (kidney)	IV 8 mg/kg monthly	57	CR = 1 PR = 9 NR = 1	Slightly elevated liver enzymes (n=1) with no discontinuation; mild thrombocytopenia 110.000/mm <sup>3</sup> (n=1) with no discontinuation
Fujikawa et al. 2013	Japan	1	M694I/- Tel Hashomer +	AOSD	No	IV 8 mg/kg monthly	/	CR = 1	/
Stein et al. 2012	Germany	5	/	crFMF	No	IV 8 mg/kg monthly	4	CR = 3 PR = 1 NR = 1	/

/ : No available data

AOSD: Adult onset Still's disease; crFMF: colchicine-resistant familial mediterranean fever; GI: gastro-intestinal; IV : intra-venous ; SC : sub-cutaneous ;

CR : complete response; NR : no response; PR: partial response